Biotherapeutics, owns stocks and filed multiple patents on ST266. Dr. Van Dyke has been a paid advisor and owns stocks in Noveome Biotheraputics. Authors' Contribution: HH substantially contributed to conception and design, acquisition, analysis, and interpretation of data; drafted and critically revised the article for important intellectual content. DS contributed to conception and design, analysis and interpretation of the data, critically revised the article. ET and TVD critically revised the manuscript with important intellectual contribution. MM and CF performed data and sample collection and data entry. MC supervised randomization, study execution and data acquisition. DN and DS performed analysis of biological specimens and critically revised the analytical sections. JS performed statistical analyses and contributed to interpretation of the results. All authors approved the final version of the article and agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. Word count: 5,146; Number of figures: 3; Number of tables: 3; Number of references: 47 Running title: Amnion-Derived Cytokine Solution for Gingivitis Treatment One sentence summary: In this Phase 1 trial oral topical application of amnion-derived cytokine solution, now termed ST266, significantly reduced the gingival inflammation in both tissue and GCF as shown by decreased level of proinflammatory cytokines.